Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2012, Article ID 473769, 8 pages
http://dx.doi.org/10.1155/2012/473769
Review Article

Dyskinesias and Treatment with Pramipexole in Patients with Parkinson's Disease

1Michael Trimble Neuropsychiatry Research Group, University of Birmingham and BSMHFT, Birmingham, UK
2Department of Neuropsychiatry and Barberry National Centre for Mental Health, University of Birmingham and BSMHFT, 25 Vincent Drive, Birmingham B15 2FG, UK
3Sobell Department of Motor Neuroscience and Movement Disorders, UCL, Institute of Neurology, London WC1N 3BG, UK

Received 1 July 2011; Revised 30 October 2011; Accepted 14 November 2011

Academic Editor: Gilberto Fisone

Copyright © 2012 John C. P. Piedad and Andrea E. Cavanna. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. B. Schulz, “Update on the pathogenesis of Parkinson's disease,” Journal of Neurology, vol. 255, no. 5, supplement, pp. 3–7, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. Parkinson Study Group, “A randomised controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD Study,” Clinical Neuropharmacology, vol. 23, no. 1, pp. 34–44, 2000. View at Google Scholar
  3. A. Schrag, Y. Ben-Shlomo, R. Brown, C. D. Marsden, and N. Quinn, “Young-onset Parkinson's disease revisited - Clinical features, natural history, and mortality,” Movement Disorders, vol. 13, no. 6, pp. 885–894, 1998. View at Google Scholar · View at Scopus
  4. R. A. Hauser, M. P. McDermott, and S. Messing, “Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease,” Archives of Neurology, vol. 63, no. 12, pp. 1756–1760, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. C. Marras, A. Lang, M. Krahn, G. Tomlinson, and G. Naglie, “Quality of life in early Parkinson's disease: impact of dyskinesia and motor fluctuations,” Movement Disorders, vol. 19, no. 1, pp. 22–28, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. S. Chapuis, L. Ouchchane, O. Metz, L. Gerbaud, and F. Durif, “Impact of the motor complications of Parkinson's disease on the quality of life,” Movement Disorders, vol. 20, no. 2, pp. 224–230, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. L. Montastruc, O. Rascol, and J. M. Senard, “Treatment of Parkinson's disease should begin with a dopamine agonist,” Movement Disorders, vol. 14, no. 5, pp. 725–730, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. W. J. Weiner, “The initial treatment of Parkinson's disease should begin with levodopa,” Movement Disorders, vol. 14, no. 5, pp. 716–724, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Constantinescu, “Update on the use of pramipexole in the treatment of Parkinson's disease,” Neuropsychiatric Disease and Treatment, vol. 4, no. 2, pp. 337–352, 2008. View at Google Scholar · View at Scopus
  10. A. Lieberman, A. Ranhosky, and D. Korts, “Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study,” Neurology, vol. 49, no. 1, pp. 162–168, 1997. View at Google Scholar · View at Scopus
  11. M. M. Pinter, O. Pogarell, and W. H. Oertel, “Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study,” Journal of Neurology Neurosurgery and Psychiatry, vol. 66, no. 4, pp. 436–441, 1999. View at Google Scholar
  12. K. S. Wong, C. S. Lu, D. E. Shan, C. C. Yang, T. H. Tsoi, and V. Mok, “Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease,” Journal of the Neurological Sciences, vol. 216, no. 1, pp. 81–87, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. J. C. Möller, W. H. Oertel, J. Köster, G. Pezzoli, and L. Provinciali, “Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial,” Movement Disorders, vol. 20, no. 5, pp. 602–610, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. C. Tanner, C. Comella, C. Kamp et al., “Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage,” Clinical Neuropharmacology, vol. 30, no. 2, pp. 72–85, 2007. View at Publisher · View at Google Scholar · View at PubMed
  15. P. Bxarone, W. Poewe, S. Albrecht et al., “Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial,” The Lancet Neurology, vol. 9, no. 6, pp. 573–580, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. W. J. Weiner, S. A. Factor, J. Jankovic et al., “The long-term safety and efficacy of pramipexole in advanced Parkinson's disease,” Parkinsonism and Related Disorders, vol. 7, no. 2, pp. 115–120, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. K. M. Shannon, J. P. Bennett, and J. H. Friedman, “Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease,” Neurology, vol. 49, no. 3, pp. 724–728, 1997. View at Google Scholar · View at Scopus
  18. L. Wermuth and The Danish Pramipexole Study Group, “A double-blind, placebo-controlled, randomised, multi-centre study of pramipexole in advanced Parkinson’s disease,” European Journal of Neurology, vol. 5, pp. 235–242, 1998. View at Google Scholar
  19. O. Pogarell, T. Gasser, J. J. van Hilten et al., “Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study,” Journal of Neurology Neurosurgery and Psychiatry, vol. 72, no. 6, pp. 713–720, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. J. P. Hubble, W. C. Koller, N. R. Cutler et al., “Pramipexole in patients with early Parkinson's disease,” Clinical Neuropharmacology, vol. 18, no. 4, pp. 338–347, 1995. View at Google Scholar · View at Scopus
  21. K. Kieburtz, “Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study,” Journal of the American Medical Association, vol. 278, no. 2, pp. 125–130, 1997. View at Google Scholar
  22. R. Holloway, I. Shoulson, K. Kieburtz et al., “Pramipexole vs Levodopa as initial treatment for Parkinson disease: a randomized controlled trial,” Journal of the American Medical Association, vol. 284, no. 15, pp. 1931–1938, 2000. View at Google Scholar
  23. P. Navan, L. J. Findley, J. A. R. Jeffs, R. K. B. Pearce, and P. G. Bain, “Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor,” Movement Disorders, vol. 18, no. 11, pp. 1324–1331, 2003. View at Publisher · View at Google Scholar · View at PubMed
  24. Parkinson Study Group, “Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomised controlled trial,” Archives of Neurology, vol. 61, pp. 1044–1053, 2004. View at Google Scholar
  25. P. Navan, L. J. Findley, M. B. Undy, R. K. B. Pearce, and P. G. Bain, “A randomly assigned double-blind cross-over study examining the relative anti-Parkinsonian tremor effects of pramipexole and pergolide,” European Journal of Neurology, vol. 12, no. 1, pp. 1–8, 2005. View at Publisher · View at Google Scholar · View at PubMed
  26. R. A. Hauser, A. H. Schapira, O. Rascol et al., “Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease,” Movement Disorders, vol. 25, no. 15, pp. 2542–2549, 2010. View at Publisher · View at Google Scholar · View at PubMed
  27. O. Rascol, P. Barone, R. A. Hauser et al., “Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease,” Movement Disorders, vol. 25, no. 14, pp. 2326–2332, 2010. View at Publisher · View at Google Scholar · View at PubMed
  28. Parkinson Study Group, “Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial,” Movement Disorders, vol. 26, no. 1, pp. 37–44, 2011. View at Google Scholar
  29. M. Guttman, “Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease,” Neurology, vol. 49, no. 4, pp. 1060–1065, 1997. View at Google Scholar
  30. Y. Mizuno, N. Yanagisawa, S. Kuno et al., “Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease,” Movement Disorders, vol. 18, no. 10, pp. 1149–1156, 2003. View at Publisher · View at Google Scholar · View at PubMed
  31. W. H. Poewe, O. Rascol, N. Quinn et al., “Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial,” The Lancet Neurology, vol. 6, no. 6, pp. 513–520, 2007. View at Publisher · View at Google Scholar · View at PubMed
  32. M. A. Brodsky, B. S. Park, and J. G. Nutt, “Effects of a dopamine agonist on the pharmacodynamics of levodopa in parkinson disease,” Archives of Neurology, vol. 67, no. 1, pp. 27–32, 2010. View at Publisher · View at Google Scholar · View at PubMed
  33. S. Fahn, R. L. Elton, and UPDRS Development Committee, “Unified Parkinson’s disease rating scale,” in Recent Developments in Parkinson’s Disease, S. Fahn, C. D. Marsden, D. B. Calne, and M. Goldstein, Eds., pp. 153–163, Macmillan, Florham Park, NJ, USA, 1987. View at Google Scholar
  34. W. Guy, “Abnormal involuntary movement scale,” in The ECDEU Assessment Manual for Psychopharmacology, US Department of Health Education and Welfare, National Institute of Health Education and Welfare, and National Institute of Mental Health, Eds., pp. 534–537, US Government Printing Office, Washington, DC, USA, 1976. View at Google Scholar
  35. R. Holloway, K. Marek, K. Biglan et al., “Long-term effect of initiating Pramipexole vs Levodopa in early Parkinson disease,” Archives of Neurology, vol. 66, no. 5, pp. 563–570, 2009. View at Publisher · View at Google Scholar
  36. P. Jenner, “Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation,” Neurology, vol. 62, no. 1, pp. S47–S55, 2004. View at Google Scholar
  37. P. Barone, “Clinical strategies to prevent and delay motor complications,” Neurology, vol. 61, no. 6, supplement, pp. S12–S16, 2003. View at Google Scholar
  38. L. A. Smith, M. J. Jackson, L. Johnston et al., “Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates,” Clinical Neuropharmacology, vol. 29, no. 3, pp. 112–125, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. W. Eisenreich, B. Sommer, S. Hartter, and W. H. Jost, “Pramipexole extended release: a novel treatment option in Parkinson's disease,” Parkinson's Disease, vol. 2010, Article ID 612619, 7 pages, 2010. View at Publisher · View at Google Scholar · View at PubMed
  40. P. Damier, L. Tremblay, J. Féger, and E. C. Hirsch, “Development of dyskinesias induced by treatment for parkinson's disease: potential role of first exposure to L-DOPA (priming),” Revue Neurologique, vol. 156, no. 3, pp. 224–235, 2000. View at Google Scholar